$ABUS
Arbutus Biopharma Corp

2022 Q3 Form 10-Q Financial Statement

#000144702822000047 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $5.952M $14.24M $12.58M
YoY Change 78.2% 511.46% 495.41%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.493M $5.200M $4.892M
YoY Change -15.75% 16.99% 27.06%
% of Gross Profit
Research & Development $20.06M $22.94M $18.46M
YoY Change 23.04% 45.21% 33.96%
% of Gross Profit
Depreciation & Amortization $343.0K $383.0K $394.0K
YoY Change -23.27% -12.16% -11.06%
% of Gross Profit
Operating Expenses $23.76M $28.35M $23.56M
YoY Change 9.27% 35.19% 32.41%
Operating Profit -$17.81M -$14.11M -$10.97M
YoY Change -3.24% -24.32% -29.99%
Interest Expense $429.0K $482.0K $506.0K
YoY Change -43.7% -36.83% -34.46%
% of Operating Profit
Other Income/Expense, Net $244.0K -$83.00K -$347.0K
YoY Change -132.53% -88.86% -50.78%
Pretax Income -$17.57M -$14.19M -$11.32M
YoY Change -8.3% -26.8% -30.89%
Income Tax $0.00 $0.00 $4.444M
% Of Pretax Income
Net Earnings -$17.57M -$14.19M -$15.77M
YoY Change -8.3% -26.8% -3.76%
Net Earnings / Revenue -295.14% -99.66% -125.31%
Basic Earnings Per Share -$0.12 -$0.10 -$0.11
Diluted Earnings Per Share -$0.12 -$0.10 -$0.11
COMMON SHARES
Basic Shares Outstanding 150.0M shares 148.8M shares 148.4M shares
Diluted Shares Outstanding 151.0M shares 148.8M shares 148.4M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $134.7M $150.2M $165.5M
YoY Change 10.97% 91.63% 25.4%
Cash & Equivalents $24.00M $47.32M $81.33M
Short-Term Investments $110.7M $102.9M $84.15M
Other Short-Term Assets $4.583M $5.622M $5.908M
YoY Change 32.23% 48.38% 44.1%
Inventory
Prepaid Expenses
Receivables $1.835M $1.970M $1.313M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $141.1M $157.8M $172.7M
YoY Change 11.54% 89.05% 25.74%
LONG-TERM ASSETS
Property, Plant & Equipment $5.241M $5.493M $5.664M
YoY Change -17.49% -18.97% -13.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $0.00
YoY Change
Other Assets $167.0K $180.0K $190.0K
YoY Change
Total Long-Term Assets $62.67M $58.05M $64.18M
YoY Change 60.43% 11.82% 621.19%
TOTAL ASSETS
Total Short-Term Assets $141.1M $157.8M $172.7M
Total Long-Term Assets $62.67M $58.05M $64.18M
Total Assets $203.8M $215.8M $236.9M
YoY Change 23.07% 59.43% 61.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $872.0K $0.00 $1.194M
YoY Change -16.31% -100.0% 198.5%
Accrued Expenses $11.76M $12.85M $7.960M
YoY Change 30.13% 93.36% 30.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $27.51M $29.82M $32.41M
YoY Change 171.99% 237.34% 384.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $30.78M $32.87M $38.62M
YoY Change 21.45% 27.87% 52.06%
Total Long-Term Liabilities $30.78M $32.87M $38.62M
YoY Change 21.45% 27.87% 52.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.51M $29.82M $32.41M
Total Long-Term Liabilities $30.78M $32.87M $38.62M
Total Liabilities $58.28M $62.69M $71.03M
YoY Change 64.38% 81.47% 121.35%
SHAREHOLDERS EQUITY
Retained Earnings -$1.182B -$1.164B -$1.150B
YoY Change 6.24% 6.99% 7.94%
Common Stock $1.308B $1.298B $1.298B
YoY Change 22.7% 27.62% 28.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $145.5M $153.1M $165.8M
YoY Change
Total Liabilities & Shareholders Equity $203.8M $215.8M $236.9M
YoY Change 23.07% 59.43% 61.98%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$17.57M -$14.19M -$15.77M
YoY Change -8.3% -26.8% -3.76%
Depreciation, Depletion And Amortization $343.0K $383.0K $394.0K
YoY Change -23.27% -12.16% -11.06%
Cash From Operating Activities -$18.69M -$20.29M $20.62M
YoY Change 16.56% 44.85% -215.31%
INVESTING ACTIVITIES
Capital Expenditures -$91.00K -$212.0K $75.00K
YoY Change 355.0% -66.4% -24.24%
Acquisitions
YoY Change
Other Investing Activities -$13.65M -$13.62M -$59.98M
YoY Change -185.35% -64.27% -427.41%
Cash From Investing Activities -$13.74M -$13.83M -$60.06M
YoY Change -186.03% -64.31% -429.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.132M 113.0K $11.49M
YoY Change -80.55% -97.37% -57.26%
NET CHANGE
Cash From Operating Activities -18.69M -20.29M $20.62M
Cash From Investing Activities -13.74M -13.83M -$60.06M
Cash From Financing Activities 9.132M 113.0K $11.49M
Net Change In Cash -23.30M -34.01M -$27.95M
YoY Change -149.69% -29.82% -202.88%
FREE CASH FLOW
Cash From Operating Activities -$18.69M -$20.29M $20.62M
Capital Expenditures -$91.00K -$212.0K $75.00K
Free Cash Flow -$18.60M -$20.08M $20.54M
YoY Change 16.14% 50.09% -214.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001447028
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34949
dei Entity Registrant Name
EntityRegistrantName
ARBUTUS BIOPHARMA CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0597776
dei Entity Address Address Line1
EntityAddressAddressLine1
701 Veterans Circle
dei Entity Address City Or Town
EntityAddressCityOrTown
Warminster
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
18974
dei City Area Code
CityAreaCode
267
dei Local Phone Number
LocalPhoneNumber
469-0914
dei Security12b Title
Security12bTitle
Common Shares, without par value
dei Trading Symbol
TradingSymbol
ABUS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
149950606 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47320000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109282000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
102879000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
46035000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1970000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
899000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5622000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4445000 usd
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
16973000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
157791000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
160661000 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10132000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9374000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5493000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5983000 usd
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
50450000 usd
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
35688000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1922000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2092000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
180000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
61000 usd
CY2022Q2 us-gaap Assets
Assets
215836000 usd
CY2021Q4 us-gaap Assets
Assets
204485000 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
12474000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10838000 usd
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
377000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
29824000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11221000 usd
CY2022Q2 abus Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
14233000 usd
CY2021Q4 abus Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
16296000 usd
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10842000 usd
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 usd
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5707000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5298000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2088000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2231000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
62694000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
35046000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
35046000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
35046000 usd
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
148794262 shares
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1164304000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1134347000 usd
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
148794262 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
144987736 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
144987736 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
1298409000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1286636000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69134000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65485000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-50097000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-48335000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
153142000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
169439000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
215836000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204485000 usd
CY2022Q2 us-gaap Revenues
Revenues
14241000 usd
CY2021Q2 us-gaap Revenues
Revenues
2329000 usd
us-gaap Revenues
Revenues
26822000 usd
us-gaap Revenues
Revenues
4442000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22942000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15799000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41404000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29581000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5200000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4478000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10092000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8356000 usd
CY2022Q2 abus Increase Decrease In Fair Value Of Contingent Consideration Liability
IncreaseDecreaseInFairValueOfContingentConsiderationLiability
208000 usd
CY2021Q2 abus Increase Decrease In Fair Value Of Contingent Consideration Liability
IncreaseDecreaseInFairValueOfContingentConsiderationLiability
694000 usd
abus Increase Decrease In Fair Value Of Contingent Consideration Liability
IncreaseDecreaseInFairValueOfContingentConsiderationLiability
409000 usd
abus Increase Decrease In Fair Value Of Contingent Consideration Liability
IncreaseDecreaseInFairValueOfContingentConsiderationLiability
823000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
28350000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
555000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
70000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
482000 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
20971000 usd
us-gaap Operating Expenses
OperatingExpenses
51905000 usd
us-gaap Operating Expenses
OperatingExpenses
38760000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14109000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18642000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-25083000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-34318000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
396000 usd
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
31000 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
763000 usd
us-gaap Interest Expense
InterestExpense
988000 usd
us-gaap Interest Expense
InterestExpense
1535000 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3000 usd
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-13000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
15000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-83000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-745000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-430000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1450000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14192000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19387000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25513000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35768000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4444000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14192000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19387000 usd
us-gaap Net Income Loss
NetIncomeLoss
-29957000 usd
us-gaap Net Income Loss
NetIncomeLoss
-35768000 usd
CY2022Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 usd
CY2021Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
3266000 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
6478000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14192000 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22653000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29957000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42246000 usd
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148750048 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148750048 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96869805 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96869805 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148589711 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148589711 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95153545 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95153545 shares
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-691000 usd
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-31000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-1762000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-28000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14883000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19418000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31719000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35796000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
169439000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1736000 usd
CY2022Q1 abus Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards
AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards
21000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
236000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1071000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15765000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
165845000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2064000 usd
CY2022Q2 abus Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards
AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards
3000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
113000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-691000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14192000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
153142000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
101966000 usd
CY2021Q1 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
0 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1647000 usd
CY2021Q1 abus Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards
AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards
40000 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26419000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
208000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
247000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16381000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
114149000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1758000 usd
CY2021Q2 abus Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards
AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards
51000 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4274000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-31000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19387000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
100829000 usd
us-gaap Net Income Loss
NetIncomeLoss
-29957000 usd
us-gaap Net Income Loss
NetIncomeLoss
-35768000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
777000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
879000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
20000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3800000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3378000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-44000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
409000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
823000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31890000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
84619000 usd
abus Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
3048000 usd
abus Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
2103000 usd
abus Non Cash Interest Expense Related To Sale Of Future Royalties
NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
985000 usd
abus Non Cash Interest Expense Related To Sale Of Future Royalties
NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
1531000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-251000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-453000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1071000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-14000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1126000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
441000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1660000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-582000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
27815000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-149000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-118000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
326000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
54145000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
11000000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
34350000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
20000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
287000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
731000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-73886000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20526000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
121000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
223000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
236000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
247000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11598000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31163000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-44000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-61962000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21297000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
109282000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52251000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47320000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30954000 usd
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
0 usd
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
6478000 usd
us-gaap Nature Of Operations
NatureOfOperations
Nature of business and future operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of the Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arbutus Biopharma Corporation (“Arbutus” or the “Company”) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company’s current focus areas include Hepatitis B virus (“HBV”), SARS-CoV-2, and coronaviruses. In HBV, the Company is developing an RNA interference (“RNAi”) therapeutic, an oral capsid inhibitor, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV infection (“cHBV”) by suppressing viral replication, reducing surface antigen and reawakening the immune system. The Company believes its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening, and is currently being evaluated in multiple phase 2 clinical trials. The Company has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronaviruses, including SARS-CoV-2. The Company is also exploring oncology applications for its internal PD-L1 portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2022, the Company had an aggregate of $200.6 million in cash, cash equivalents and investments in marketable securities. The Company had no outstanding debt as of June 30, 2022. The Company believes it has sufficient cash resources to fund its operations for at least the next 12 months. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company’s research and development activities and the commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company’s existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">COVID-19 Impact </span></div>The COVID-19 pandemic has resulted in and will likely continue to result in significant disruptions to businesses. Measures implemented around the world in attempts to slow the spread of COVID-19 have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, including shortages and delays in the supply chain and prohibitions in certain countries on enrolling patients in new clinical trials. While the Company has been able to progress with its clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will materially impact the Company’s plans and timelines in the future.
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
200600000 usd
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
0 usd
CY2022Q2 abus Wholly Owned Subsidiaries Includedin Financial Statements
WhollyOwnedSubsidiariesIncludedinFinancialStatements
1 subsidiary
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35400000 shares
CY2021Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
22833922 shares
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5700000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
400000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5298000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
409000 usd
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5707000 usd
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
3426000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
823000 usd
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
4249000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
102900000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
50500000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
46000000 usd
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
35700000 usd
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
CY2022Q2 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
CY2021Q2 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
CY2022Q2 us-gaap Equity Method Investments
EquityMethodInvestments
0 usd
CY2022Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
0 usd
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
3174000 usd
CY2022Q2 abus Accrued Research And Development
AccruedResearchAndDevelopment
9455000 usd
CY2021Q4 abus Accrued Research And Development
AccruedResearchAndDevelopment
2371000 usd
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
415000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
983000 usd
CY2022Q2 abus Accrued Payroll Current
AccruedPayrollCurrent
2632000 usd
CY2021Q4 abus Accrued Payroll Current
AccruedPayrollCurrent
4279000 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
-28000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
31000 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
12474000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10838000 usd
CY2021Q4 abus Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
16296000 usd
CY2020Q4 abus Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
19554000 usd
us-gaap Premiums Earned Net
PremiumsEarnedNet
4100000 usd
abus Liability From Sale Of Future Royalties Non Cash Royalty Income
LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome
3048000 usd
abus Liability From Sale Of Future Royalties Non Cash Royalty Income
LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome
2103000 usd
abus Liability From Sale Of Future Royalties Non Cash Expense
LiabilityFromSaleOfFutureRoyaltiesNonCashExpense
985000 usd
abus Liability From Sale Of Future Royalties Non Cash Expense
LiabilityFromSaleOfFutureRoyaltiesNonCashExpense
1531000 usd
CY2022Q2 abus Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
14233000 usd
CY2021Q2 abus Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
18982000 usd
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
27815000 usd
CY2022Q2 abus Royalty Entitlements
RoyaltyEntitlements
2 product
CY2022Q2 us-gaap Revenues
Revenues
14241000 usd
CY2021Q2 us-gaap Revenues
Revenues
2329000 usd
us-gaap Revenues
Revenues
26822000 usd
us-gaap Revenues
Revenues
4442000 usd
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1164000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.33
CY2021Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.03
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.78
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2065000 usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.23
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1743000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3800000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3378000 usd
CY2021Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
22833922 shares

Files In Submission

Name View Source Status
0001447028-22-000047-index-headers.html Edgar Link pending
0001447028-22-000047-index.html Edgar Link pending
0001447028-22-000047.txt Edgar Link pending
0001447028-22-000047-xbrl.zip Edgar Link pending
a2022-q210xqex311.htm Edgar Link pending
a2022-q210xqex312.htm Edgar Link pending
a2022-q210xqex321.htm Edgar Link pending
a2022-q210xqex322.htm Edgar Link pending
abus-20220630.htm Edgar Link pending
abus-20220630.xsd Edgar Link pending
abus-20220630_cal.xml Edgar Link unprocessable
abus-20220630_def.xml Edgar Link unprocessable
abus-20220630_g1.jpg Edgar Link pending
abus-20220630_htm.xml Edgar Link completed
abus-20220630_lab.xml Edgar Link unprocessable
abus-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending